Suppr超能文献

新辅助治疗后经肛门局部切除与全直肠系膜切除治疗直肠癌的长期疗效:一项荟萃分析。

Long-term efficacy of transanal local excision versus total mesorectal excision after neoadjuvant treatment for rectal cancer: A meta-analysis.

机构信息

The School of Clinical Medical, Fujian Medical University, Fuzhou, Fujian, China.

Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.

出版信息

PLoS One. 2023 Nov 20;18(11):e0294510. doi: 10.1371/journal.pone.0294510. eCollection 2023.

Abstract

AIM

The purpose of this meta-analysis is to compare the long-term efficacy of transanal local excision (TLE) versus total mesorectal excision (TME) following neoadjuvant therapy for rectal cancer.

METHOD

The Web of Science, Pubmed, Medline, Embase, and the Cochrane Library were systematically searched for correlational research. The Newcastle-Ottawa Scale and the Cochrane risk of bias tool were used to assess the quality of cohort studies (CSs) and randomized controlled trials (RCTs), respectively. Statistically analyzed using RevMan5.4.

RESULT

A total of 13 studies, including 3 randomized controlled trials (RCTs) and 10 cohort studies (CSs), involving 1402 patients, were included in the analysis. Of these, 570 patients (40.66%) underwent TLE, while 832 patients (59.34%) underwent TME. In the meta-analysis of CSs, no significant difference was observed between the TLE group and TME group regarding 5-year overall survival (OS) and 5-year disease-free survival (DFS) (P > 0.05). However, the TLE group had a higher rates of local recurrence (LR) [risk ratio (RR) = 1.93, 95%CI (1.18, 3.14), P = 0.008] and a lower rates of 5-years local recurrence-free survival (LRFS) [hazard ratio (HR) = 2.79, 95%CI (1.04, 7.50), P = 0.04] compared to the TME group. In the meta-analysis of RCTs, there was no significant difference observed between the TLE group and TME group in terms of LR, 5-year OS, 5-year DFS, and 5-year disease-specific survival (P > 0.05).

CONCLUSION

After undergoing neoadjuvant therapy, TLE may provide comparable 5-year OS and DFS to TME for rectal cancer. However, neoadjuvant therapy followed by TLE may has a higher LR and lower 5-year LRFS compared to neoadjuvant therapy followed by TME, so patients should be carefully selected. Neoadjuvant therapy followed by TLE may be a suitable option for patients who prioritize postoperative quality of life. However, the effectiveness of this approach requires further research to draw a definitive conclusion.

摘要

目的

本荟萃分析旨在比较直肠癌新辅助治疗后经肛局部切除术(TLE)与全直肠系膜切除术(TME)的长期疗效。

方法

系统检索了 Web of Science、PubMed、Medline、Embase 和 Cochrane 图书馆的相关研究。采用纽卡斯尔-渥太华量表和 Cochrane 偏倚风险工具分别评估队列研究(CSs)和随机对照试验(RCTs)的质量。采用 RevMan5.4 进行统计学分析。

结果

共纳入 13 项研究,包括 3 项随机对照试验(RCTs)和 10 项队列研究(CSs),共 1402 例患者。其中,570 例(40.66%)患者行 TLE,832 例(59.34%)患者行 TME。CS 荟萃分析显示,TLE 组与 TME 组 5 年总生存率(OS)和 5 年无病生存率(DFS)无显著差异(P>0.05)。然而,TLE 组局部复发率(LR)更高[风险比(RR)=1.93,95%CI(1.18,3.14),P=0.008],5 年局部无复发生存率(LRFS)更低[风险比(HR)=2.79,95%CI(1.04,7.50),P=0.04]。RCT 荟萃分析显示,TLE 组与 TME 组在 LR、5 年 OS、5 年 DFS 和 5 年疾病特异性生存率方面无显著差异(P>0.05)。

结论

新辅助治疗后,TLE 与 TME 治疗直肠癌的 5 年 OS 和 DFS 可能相当。然而,新辅助治疗后行 TLE 可能比新辅助治疗后行 TME 具有更高的 LR 和更低的 5 年 LRFS,因此应谨慎选择患者。对于重视术后生活质量的患者,新辅助治疗后行 TLE 可能是一种合适的选择。然而,这种方法的有效性需要进一步研究才能得出明确结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f2/10659211/c0d97652d566/pone.0294510.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验